


Rova-T IO Combination Study (M16-300)

Study Design and Endpoints¹

Multicenter, Phase 1/2, open-label, study to assess the safety and efficacy of rovalpituzumab tesirine (Rova-T) administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung carcinoma (SCLC)



Key Inclusion Criteria

- Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematologic, hepatic, and renal function

Key Exclusion Criteria

- Active, known, or suspected autoimmune disease
- Prior exposure to an immuno-oncology or pyrrolbenzodiazepine (PBD)-based drug

Rova-T is an investigational drug which has not been approved by regulatory health agencies. Efficacy and safety have not been established.

Safety will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) and as defined by study protocol.

1. <https://clinicaltrials.gov/ct2/show/NCT03026166> (accessed April 2018)

To learn more about our pipeline, please visit www.abbvie.com/oncology

To learn more about these studies, please visit <https://ClinicalTrials.gov> or email abbvieclinicaltrials@abbvie.com

abbvie